RE:RE:RE:RE:RE:Marketing EffortsLife is tough for junior pharma/medical device companies and that's been clearly evident in the case of Ventripoint. Their cash tank is always running on fumes and the institutions have their nostrils flared at the smell of this blood and sell to hold the price down .....and their selling anywhere above five cents earns them a profit to boot. They have their sights set on another low cost financing.<br /> <br /> What we need to see is China in with a licensing agreement and the actual influx of cash that this company needs. Institutions get burned in some small way and share price gives us the "YaHoo" and "Yippee Ki Yay" that we are looking for. Then onwards and upwards from there. <br /> <br /> My Humble Opinion